A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Clinical Trial

Study Details

Status

RECRUITING

Study ID #

NCT07081646

Study Start

2025-08-18

Primary Completion

2029-08-15

Study Completion

2031-02-14

Enrollment

Study Type

Interventional

Phase

Phase 1

Phase 2

Study Overview

Summary

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Conditions

Relapsed AL Amyloidosis

Refractory AL Amyloidosis

Light Chain Amyloidosis

Amyloidosis

Contacts and Locations

Study Contact

Name

Alexion Pharmaceuticals, Inc. (Sponsor)

Role

Contact

Phone

1-855-752-2356

clinicaltrials@alexion.com

Facility

Research Site
Phoenix, Arizona 85028
United States

Facility

Research Site
San Francisco, California 94143
United States

Facility

Research Site
Tampa, Florida 33612
United States

Facility

Research Site
Boston, Massachusetts 02215
United States

Facility

Research Site
Detroit, Michigan 48201
United States

Facility

Research Site
Rochester, Minnesota 55905
United States

Facility

Research Site
St Louis, Missouri 63110
United States

Facility

Research Site
New York, New York 10016
United States

Facility

Research Site
New York, New York 10032
United States

Facility

Research Site
New York, New York 10065
United States

Facility

Research Site
Cleveland, Ohio 44195
United States

Facility

Research Site
Nashville, Tennessee 37232
United States

Facility

Research Site
Calgary Alberta T2N 5G2
Canada

Facility

Research Site
Calgary Alberta T2N 5G2
Canada

Facility

Research Site
Toronto Ontario M5G 2M9
Canada

Facility

Research Site
Toronto Ontario M5G 2M9
Canada

Facility

Research Site
London
NW3 2PF
United Kingdom

Facility

Research Site
London
NW3 2PF
United Kingdom